- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Severe eosinophilic asthma is a rare type of asthma, that do not respond t the usually asthma drug treatments (corticosteroids). That means that it’s harder to manage, so asthma attacks will possibly occur. This type of asthma involves the abnormal production of type 2 cytokines from T-helper 2 and innate lymphoid cells.
Showing all 4 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
IL-5 receptor alpha |
Monoclonal Antibody |
Fasenra® |
30 mg/mL |
– |
1,5 mg |
tba |
tba |
733,00 € |
||
IL-13 , IL-4 |
Monoclonal Antibody |
Dupixent® |
150 mg/mL |
– |
12 mg |
-80°C |
10/2023 |
290,70 € |
||
IL-13 , IL-4 |
Monoclonal Antibody |
Dupixent® |
150 mg/mL |
yes |
12 mg |
-80°C |
11/2024 |
375,00 € |
||
IL-5 |
Monoclonal Antibody |
Nucala® |
100 mg/mL |
– |
4 mg |
-80 °C |
08/2025 |
434,00 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin